Percutaneous Coronary Intervention (PCI) Clinical Trials

Clinical trials related to Percutaneous Coronary Intervention (PCI) Procedure

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention: A Randomized Double-Blind Pilot Study (EZ-STAR)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Age 19 years or older at the time of providing informed consent.

• Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.

• Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.

• Patients who have voluntarily provided written informed consent to participate in this clinical study.

Locations
Other Locations
Republic of Korea
Yongin Severance Hospital, Yonsei University
RECRUITING
Yongin-si
Contact Information
Primary
Yongcheol Kim, MD, PhD
yongcheol@yuhs.ac
+82-031-5189-8967
Time Frame
Start Date: 2026-04-02
Estimated Completion Date: 2028-07-12
Participants
Target number of participants: 100
Treatments
Experimental: zastaprazan 20mg
Participants receive zastaprazan 20mg and Placebo matching Pariet 10mg tablet 10mg.
Experimental: Pariet 10mg
Participants receive Pariet 10mg and Placebo matching zastaprazan 20mtablet 10mg.
Sponsors
Leads: Yonsei University
Collaborators: Jeil Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov